Company Filing History:
Years Active: 2007
Title: Fred H Marmelstein: Innovator in Neoplastic Disease Treatment
Introduction
Fred H Marmelstein is a notable inventor based in Clifton, NJ (US). He has made significant contributions to the field of biopharmaceuticals, particularly in the treatment of neoplastic diseases. With a total of two patents to his name, Marmelstein's work focuses on innovative methods that utilize arsenic compounds for therapeutic purposes.
Latest Patents
Marmelstein's latest patents revolve around compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds. The invention details the administration of arsenic in various forms, including salts, complexes, organic compounds, or ionic solutions. This approach aims to treat tumors affecting epithelial tissue, connective tissue, the central nervous system, lymphoid tissue, and hematopoietic cells, as well as tumors associated with oncogenic viruses. Additionally, the invention addresses the treatment of hematopoietic disorders in mammals through the administration of arsenic compounds, which may also be effective against metastatic neoplastic diseases.
Career Highlights
Marmelstein is currently associated with Polarx Biopharmaceuticals, Inc., where he continues to advance his research and development efforts. His work has the potential to impact the treatment landscape for various cancers, providing new avenues for patient care.
Collaborations
Marmelstein collaborates with Ralph M Ellison, contributing to the innovative research environment at Polarx Biopharmaceuticals, Inc. Their combined expertise enhances the development of effective treatments for neoplastic diseases.
Conclusion
Fred H Marmelstein's contributions to the field of biopharmaceuticals, particularly through his innovative patents, highlight his commitment to improving treatment options for neoplastic diseases. His work exemplifies the intersection of science and medicine, paving the way for future advancements in cancer therapy.